Table 1.
Baseline characteristics for CM and non-CM users in colorectal cancer patients from CO.20, 21, and 23.
| Variable | CM yes (%) N = 251 | CM no (%) N = 1353 | Total (%) | Univariate P value |
|---|---|---|---|---|
| Gender | ||||
| Female | 90 (35.9) | 481 (35.6) | 571 (35.6) | .926 |
| Male | 161 (64.1) | 872 (64.4) | 1033 (64.4) | |
| Age ∗∗ | ||||
| ≤65 | 167 (66.5) | 745 (55.1) | 912 (56.9) | .001 |
| >65 | 84 (33.5) | 608 (44.9) | 692 (43.1) | |
| ECOG Performance Status ∗∗ | ||||
| ECOG PS 0 or 1 | 236 (94.0) | 1159 (85.7) | 1395 (87.0) | <.001 |
| ECOG PS 2 or 3 | 15 (6.0) | 194 (14.3) | 209 (13.0) | |
| Presence of liver metastases | ||||
| No | 62 (24.7) | 338 (25.0) | 400 (24.9) | .925 |
| Yes | 189 (75.3) | 1015 (75.0) | 1204 (75.1) | |
| Number of previous chemo drug classes | ||||
| >2 | 240 (95.6) | 1306 (96.5) | 1546 (96.4) | .479 |
| ≤2 | 11 (4.4) | 47 (3.5) | 58 (3.6) | |
| Number of disease sites ∗∗ | ||||
| >2 | 65 (25.9) | 509 (37.6) | 574 (35.8) | < .001 |
| ≤2 | 186 (74.1) | 844 (62.4) | 1030 (64.2) | |
| Hemoglobin ∗∗ | ||||
| Grade ≥1 | 132 (52.6) | 913 (67.5) | 1045 (65.1) | < .001 |
| Grade 0 | 119 (47.4) | 440 (32.5) | 559 (34.9) | |
| LDH | ||||
| Missing | 4 (1.6) | 57 (4.2) | 61 (3.8) | .089 |
| >UNL | 154 (61.4) | 880 (65.0) | 1034 (64.5) | |
| ≤UNL | 93 (37.1) | 416 (30.7) | 509 (31.7) | |
| Alkaline phosphatase | ||||
| Missing | 2 (0.8) | 12 (0.9) | 14 (0.9) | .440 |
| >UNL | 155 (61.8) | 869 (64.2) | 1024 (63.8) | |
| ≤UNL | 94 (37.5) | 472 (34.9) | 566 (35.3) | |
| Study treatment in each trial | ||||
| Napabucasin + BSC (CO23) | 21 (8.4) | 117 (8.6) | 138 (8.6) | .031 |
| Placebo + BSC (CO23) | 23 (9.2) | 121 (8.9) | 144 (9.0) | |
| BSC (CO17) | 34 (13.5) | 251 (18.6) | 285 (17.8) | |
| Cetuximab + BSC (CO17) | 51 (20.3) | 236 (17.4) | 287 (17.9) | |
| Cetuximab + Brivanib (CO20) | 47 (18.7) | 329 (24.3) | 376 (23.4) | |
| Cetuximab + Placebo (CO20) | 75 (29.9) | 299 (22.1) | 374 (23.3) | |
∗∗Significance in univariate and multivariate analysis (P < .05)